Kaitlyn Kosko

DocwireNews

Radiation therapy with helical tomotherapy (HT) is safe and provides a survival advantage in patients with malignant pleural mesothelioma (MPM) who underwent lung-sparing surgery. Furthermore, superior survival was seen in patients who also received adjuvant chemotherapy, according to lead author Julian P. Layer, MD.&nbsp; The study&rsquo;s primary end points included local control, distant control, progression-free survival (PFS), and overall survival (OS) in patients with MPM receiving intensity-modulated HT.Thirty-four patients, who were a median age of 65 years and mostly men (77.4%), were included in the evaluation. Prior to radiation therapy, 21 (67.7%) patients underwent total or partial surgical pleurectomy. Eighteen (58.1%) patients received neoadjuvant platinum-based chemotherapy, 13 (41.9%) received adjuvant platinum-based chemotherapy, and two (6.5%) received no prior perioperative systemic therapy.At a median follow-up of 20 months, local control and distant control were a median of 23 months. In addition, a median PFS rate of 19 months was observed in patients with a 1-year PFS rate of 72.4% and a 2-year PFS rate of 24.1%.The median OS was 20 months. OS was 86.2% at 1 year and 41.4% at 2 years. Clinical outcome can be significantly improved by using adjuvant chemotherapy (P=.008).Overall, intensity-modulated HT was well tolerated among patients with MPM. The most common adverse events (AEs) of all grades were fatigue (60.0%), dysphagia (50.1%), and nausea (40.0%).Dysphagia (16.7%), dyspnea (6.7%), and pain (3.3%) were among the grade 3 AEs seen in 26.7% of patients.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Survival, Safety Data for Radiation Therapy With Helical Tomotherapy in MPM

Mesothelioma

Radiation therapy with HT is safe and effective in patients with malignant pleural mesothelioma.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe